Skip to main content
Oferta
Oferta
Integrated Biologics
Integrated Biologics
Tecnologías de expresión
Tecnologías de expresión
GS Xceed® Gene Expression System
GS piggyBac® Transposon Technology
GS Effex® Cell Line
GS Discovery® Transient Expression
bYlok® Bispecific Pairing Technology
XS Technologies®
Soporte técnico
Early Derisking and Optimization
Early Derisking and Optimization
Developability Assessment
Manufacturability Assessment
Antibody Humanization and Deimmunization
Protein Engineering
Potency Assessment
Immunogenicity / Immunotoxicity Assessment
Rapid Host Screen and Early Protein Expression
Producción no conforme a las BPF
Epibase® in vitro and in silico Screening
Mammalian Biopharmaceutical Services
Mammalian Biopharmaceutical Services
Ibex® Design mAbs DNA-to-IND Program
Ibex® Design Bispecifics DNA-to-IND Program
Ibex® Design Fabs and Fc-Fusion Proteins DNA-to-IND Programs
Ibex® Design Scaffolds and other Recombinant Proteins
Cell Line Development
Tailored License Application Program
Desarrollo del proceso
Desarrollo analítico
Drug Substance Manufacturing
Parenteral Drug Product Services
Parenteral Drug Product Services
Clinical Technology Transfers
Biologics Formulatability
Product Formulation Development
Desarrollo analítico
Desarrollo del proceso
Biologics Special Services
Drug Product Manufacture
Biologics Regulatory Services
Centro de conocimientos
Advanced Synthesis
Advanced Synthesis
Moléculas pequeñas
Moléculas pequeñas
Drug Substance/API Services
Drug Substance/API Services
API Support for Early Phase Development
AI-Enabled Route Scouting Service
Solid Form Drug Services
PBPK Modeling Services
Pharmaceutical Method Development
Commercial API Manufacturing Services
Highly Potent API Technologies
Highly Potent API Technologies
HPAPI Handling and Development
HPAPI Manufacturing | Low & High Potency
ADC Clinical and Commercial Manufacturing
ADC Payload Product Development
Ingeniería de partículas
Ingeniería de partículas
Solid Dispersion Technology
Mejora de la biodisponibilidad
Spray-Dried Dispersion Technology
Micronization and Jet Milling
Hot Melt Extrusion
Producto farmacológico
Producto farmacológico
SimpliFiH® Solutions
Drug Product Technologies
Drug Product Technologies
Specialized Drug Product Development
Micro-dosing for Early Human Clinical Studies
Clinical Trial Material Manufacture, Supply
Clinical Bottling, Labelling and Supply
Formulation and Development
Design and Preformulation Development
Drug Development Workflow & Pharmaceutical Process Optimization
Pediatric Drug Product Development
Inhalation Formulation Development
Ofertas integradas
Regulatory Affairs CMC Services
Regulatory Affairs CMC Services
CMC Development Services | CMC Regulatory Submissions
Bioconjugates Services
Bioconjugates Services
Early Development Bioconjugates | ADC
ADC Drug Substance Manufacturing
Pharmaceutical, ADC Analytical Services
Targeting Agent and Carrier Protein
ADC Process Development
Ibex® Design ADC, DNA-to-IND Program
Centro de conocimientos
Specialized Modalities
Specialized Modalities
Células y genes
Células y genes
Desarrollo del proceso
Producción conforme a las BPFa
Alogénico
Autólogo
Vectores virales
Exosomas
Plataforma Cocoon®
Microbios
Microbios
Microbial Strain Development
Desarrollo del proceso
Drug Substance Manufacturing
Desarrollo analítico
mRNA/LNP
mRNA/LNP
Desarrollo del proceso
Analytical Services
mRNA Manufacturing
Lipid Nanoparticles Encapsulation
Productos biocientíficos
Centro de conocimientos
Centro de conocimientos
Compañía
Compañía
Acerca de nosotros
Acerca de nosotros
Our One Lonza Strategy
Our Leadership
Our Leadership
Executive Committee
Board of Directors
Board Committees
Our History
Our Locations
Noticias y medios
Noticias y medios
Comunicados de prensa
Imágenes y videos
Pautas sobre el logo
Blog
A View On - Lonza Podcast
Consultas de los periodistas
Relaciones con los inversores
Relaciones con los inversores
Shareholders and Stock Information
Shareholders and Stock Information
Consenso y analistas
Bond Investors and Credit Information
Investor FAQ
Share Buyback
Calendario y eventos
Informes y presentaciones
Gobernanza corporativa
Ética y cumplimiento
Consultas de los inversores
Sustentabilidad
Sustentabilidad
Medioambiente
Personas y sociedad
Cumplimiento e integridad
Adquisición responsable de materiales
Calidad Global
Empleo
Empleo
Welcome to Lonza
La vida en Lonza
Employee Benefits
Early Career Opportunities
Inclusion, Diversity and Belonging
Únase a nuestra comunidad de talentos
Contact
Search
Cancel
Inicio
Centro de conocimientos
Human-Induced Pluripotent Stem Cells Manufactured
28 de feb. de 2018
Human-Induced Pluripotent Stem Cells Manufactured
Frontiers in Medicine peer-reviewed paper on hIPSCs cGMP manufacturing.
You may also be interested in:
Alogénico
iPSC
Process Development and Optimization
Manufacturing: cGMP
Nombre
Apellido
Correo electrónico comercial
Company Name
País
Afganistán
Islas Åland
Albania
Argelia
Samoa Americana
Andorra
Angola
Anguila
Antártida
Antigua y Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaiyán
Bahamas (las)
Baréin
Bangladés
Barbados
Bielorrusia
Bélgica
Belice
Benín
Bermudas
Bután
Bolivia (Estado Plurinacional de)
Bonaire, San Eustaquio y Saba
Bosnia y Herzegovina
Botsuana
Isla Bouvet
Brasil
Territorio Británico del Océano Índico (el)
Brunéi Darusalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Camboya
Camerún
Canadá
Islas Caimán (las)
República Centroafricana (la)
Chad
Chile
China
Isla de Navidad
Islas Cocos (Keeling) (las)
Colombia
Comoras (las)
Congo (el)
Congo (la República Democrática del)
Islas Cook (las)
Costa Rica
Costa de Marfil
Croacia
Cuba
Curazao
Chipre
Chequia
Dinamarca
Yibuti
Dominica
República Dominicana (la)
Ecuador
Egipto
El Salvador
Guinea Ecuatorial
Eritrea
Estonia
Suazilandia
Etiopía
Islas Falkland (las) [Malvinas]
Islas Feroe (las)
Fiyi
Finlandia
Francia
Guayana Francesa
Polinesia Francesa
Tierras Australes y Antárticas Francesas (las)
Gabón
Gambia
Georgia
Alemania
Ghana
Gibraltar
Grecia
Groenlandia
Granada
Guadalupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bisáu
Guyana
Haití
Islas Heard y McDonald
Santa Sede (la)
Honduras
Hong Kong
Hungría
Islandia
India
Indonesia
Irán (República Islámica de)
Irak
Irlanda
Isla de Man
Israel
Italia
Jamaica
Japón
Jersey
Jordania
Kazajistán
Kenia
Kiribati
Corea (la República Popular Democrática de)
Corea (la República de)
Kuwait
Kirguistán
República Democrática Popular de Lao (la)
Letonia
Líbano
Lesoto
Liberia
Libia
Liechtenstein
Lituania
Luxemburgo
Macao
Madagascar
Malaui
Malasia
Maldivas
Mali
Malta
Islas Marshall (las)
Martinica
Mauritania
Mauricio
Mayotte
México
Micronesia (Estados Federados de)
Moldavia (la República de)
Mónaco
Mongolia
Montenegro
Montserrat
Marruecos
Mozambique
Myanmar
Namibia
Nauru
Nepal
Países Bajos (los)
Nueva Caledonia
Nueva Zelanda
Nicaragua
Níger (el)
Nigeria
Niue
Isla Norfolk
Macedonia del Norte
Islas Marianas del Norte (las)
Noruega
Omán
Pakistán
Palaos
Palestina (Estado de)
Panamá
Papúa Nueva Guinea
Paraguay
Perú
Filipinas (las)
Pitcairn
Polonia
Portugal
Puerto Rico
Catar
Reunión
Rumania
Federación Rusa (la)
Ruanda
San Bartolomé
Santa Elena, Ascensión y Tristán de Acuña
San Cristóbal y Nieves
Santa Lucía
Isla de San Martín (territorio francés)
San Pedro y Miquelón
San Vicente y las Granadinas
Samoa
San Marino
Santo Tomé y Príncipe
Arabia Saudita
Senegal
Serbia
Seychelles
Sierra Leona
Singapur
Isla de San Martín (territorio neerlandés)
Eslovaquia
Eslovenia
Islas Salomón
Somalia
Sudáfrica
Islas Georgias del Sur y Sándwich del Sur
Sudán del Sur
España
Sri Lanka
Sudán
Surinam
Svalbard y Jan Mayen
Suecia
Suiza
República Árabe Siria (la)
Taiwán (provincia de China)
Tayikistán
Tanzania (la República Unida de)
Tailandia
Timor Oriental
Togo
Tokelau
Tonga
Trinidad y Tobago
Túnez
Turquía
Turkmenistán
Islas Turcas y Caicos (las)
Tuvalu
Uganda
Reino Unido
Ucrania
Emiratos Árabes Unidos (los)
Islas Ultramarinas Menores de los Estados Unidos (las)
Estados Unidos de América
Uruguay
Uzbekistán
Vanuatu
Venezuela (República Bolivariana de)
Vietnam
Islas Vírgenes (Británicas)
Islas Vírgenes (EE. UU.)
Global
Wallis y Futuna
Sahara Occidental*
Yemen
Zambia
Zimbabue
State
Alaska
Alabama
Arkansas
Samoa Americana
Arizona
California
Colorado
Connecticut
District of Columbia
Delaware
Florida
Georgia
Guam
Hawaii
Iowa
Idaho
Illinois
Indiana
Kansas
Kentucky
Louisiana
Massachusetts
Maryland
Maine
Michigan
Minnesota
Missouri
Northern Mariana Islands
Mississippi
Montana
North Carolina
North Dakota
Nebraska
New Hampshire
New Jersey
New Mexico
Nevada
New York
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
U.S. Minor Outlying Islands (cf. separate entry UM)
Utah
Virginia
Virgin Islands of the U.S.
Vermont
Washington
Wisconsin
West Virginia
Wyoming
Join our community to receive tailored insights and resources. You can unsubscribe at any time.
By clicking "Access Content" you agree to our
Legal Disclaimer
and the
Lonza Privacy and Cookies Policy
.
Cargando…
Latest briefing from the Knowledge Center
Documento técnico
Innovations in linking rational design and material-sparing strategies for enabled intermediates and...
Did you catch our insightful webinar on Linking rational design and material-sparing strategies for...
Seminario web (a pedido)
End-to-end regulatory CDMO solutions: development, manufacturing, and approval
Navigating the journey from drug development to market can feel like a maze, with each step...
Documento técnico
Seamless commercial tech transfers in OSD manufacturing
Remember our insightful webinar on Commercial tech transfers in OSD manufacturing? If you missed it,...
Presentación (a pedido)
Challenging your AAV productivity and packaging efficiencies through a validated platform
AAV transient and stable cell line platforms represent a leap into next-generation technologies that...
CDMO Notes Blog post
Using bespoke downstream processing strategies for the purification of complex novel protein-based...
Discover how Lonza's innovative downstream processing strategies can help you overcome the...
Seminario web (a pedido)
Commercial Tech Transfers in OSD Manufacturing
This webinar explores the critical aspects of manufacturing commercial tech transfers for the...
Publicación del blog de I+D
In-use stability and compatibility of Biologics – How to safely administer an effective medicinal...
Ensuring that patients receive the highest quality treatment under the best possible conditions is a...
Seminario web (a pedido)
Rapid delivery of toxicological study material: The new critical path for accelerating...
With ever-increasing speed from DNA to IND, the window for toxicological data generation is becoming...
Documento técnico
The Role of Excipients in Inhaled Biologics
The field of inhaled biologics is rapidly expanding, with both dry and liquid formulations of...
CDMO Notes Blog post
Accelerated Tox Offerings: A Recipe for Streamlining IND Applications
Accelerating the timeline to tox material can significantly enhance the drug development process,...
Seminario web (a pedido)
Lonza Drug Product OPCU Capacity Update
Explore Lonza's end-to-end Drug Product capabilities along the full life cycle, seamlessly...
Seminario web (a pedido)
De-Risking Early Phase Micronization with Integrated Solid Form Selection
Achieving the right particle size for respiratory drug delivery is crucial, and jet milling is a...
Anterior
Siguiente
Configuración de cookies
|
Términos y condiciones
|
Exención de responsabilidad legal
|
Política de privacidad